pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Canagliflozin
Phase 3 · small molecule · Diabetes Mellitus, Type 2
Canagliflozin for Diabetes Mellitus, Type 2 is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Internal code CR017011
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen Cilag International NV
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Diabetes Mellitus, Type 2
- Status
- completed
- Trials
- 1